Role of ADHD symptoms as a contributing factor to obesity in patients with MC4R mutations

Medical Hypotheses

Volumn 84, Issue 1, 2015, Pages 4-7

  Porfirio, Maria Cristina ^a   Giovinazzo, Silvia ^a   Cortese, Samuele ^b,c,d,e   Giana, Grazia ^a   Lo Castro, Adriana ^a   Mouren, Marie Christine ^f   Curatolo, Paolo ^a   Purper Ouakil, Diane ^g,h  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b CAMBRIDGE UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^c UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^d UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^e NEW YORK UNIVERSITY CHILD STUDY CENTER   (United States)

^f HÔPITAL ROBERT DEBRÉ   (France)

^g HÔPITAL SAINT ELOI   (France)

^h CENTRE DE PSYCHIATRIE ET NEUROSCIENCES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ATOMOXETINE; LEPTIN; MELANOCORTIN 4 RECEPTOR; METHYLPHENIDATE; MC4R PROTEIN, HUMAN;

AMYGDALOID NUCLEUS; ARTICLE; ATTENTION DEFICIT DISORDER; BINGE EATING DISORDER; BODY WEIGHT; BRAIN STEM; FEEDING BEHAVIOR; GENE MUTATION; GENETIC SCREENING; GENETIC SUSCEPTIBILITY; HUMAN; HYPOTHALAMUS; IMPULSIVENESS; LOCOMOTION; MC4R GENE; OBESITY; OVERNUTRITION; PHENOTYPE; RECEPTOR GENE; REWARD; SPINAL CORD; THALAMUS; VENTRAL TEGMENTUM; WEIGHT REDUCTION; BIOLOGICAL MODEL; COMPLICATION; GENETICS; MUTATION; PHYSIOLOGY;

ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; FEEDING BEHAVIOR; HUMANS; MODELS, BIOLOGICAL; MUTATION; OBESITY; RECEPTOR, MELANOCORTIN, TYPE 4; REWARD;

EID: 84918498529     PISSN: 03069877     EISSN: 15322777     Source Type: Journal    
DOI: 10.1016/j.mehy.2014.11.004     Document Type: Article

References (29)

1. Popkin B.M., Slining M.M. New dynamics in global obesity facing low- and middle-income countries. Obes Rev 2013, 14(2):11-20.
2. World Health Organization Press. Global status report on noncommunicable diseases 2010; 2011.
3. Beckers S., Zegers D., de Freitas F., Peeters A.V., Verhulst S.L., Massa G., et al. Identification and functional characterization of novel mutations in the melanocortin-4 receptor. Obes Facts 2010, 3(5):304-311.
4. Adan R.A., Tiesjema B., Hillebrand J.J., la Fleur S.E., Kas M.J., de Krom M. The MC4 receptor and control of appetite. Br J Pharmacol 2006, 149(7):815-827.
5. Farooqi I.S., Keogh J.M., Yeo G.S.H., Lank E.J., Cheetham T., O' Rahilly S. Clinical spectrum of obesity and mutations in the melanocortin 4 receptor gene. N Engl J Med 2003, 348:1085-1095.
6. Martinelli C.E., Keogh J.M., Greenfield J.R., Henning E., van der Klaauw A.A., Blackwood A., et al. Obesity due to melanocortin 4 receptor (MC4R) deficiency is associated with increased linear growth and final height, fasting hyperinsulinemia, and incompletely suppressed growth hormone secretion. J Clin Endocrinol Metab 2011, 96(1):E181-E188.
7. Branson R., Potoczna N., Kral J., Lentes K.-U., Hoehe M., Horber F. Binge eating as a major phenotype of melanocortin 4 receptor mutations. N Engl J Med 2003, 348(12):1096-1103.
8. Albayrak O., Albrecht B., Scherag S., Barth N., Hinney A., Hebebrand J. Successful methylphenidate treatment of early onset extreme obesity in a child with a melanocortin-4 receptor gene mutation and attention deficit/hyperactivity disorder. Eur J Pharmacol 2011, 3.
9. Agranat-Meged A., Ghanadri Y., Eisenberg I., Ben Neriah Z., Kieselstein-Gross E., Mitrani-Rosenbaum S. Attention deficit hyperactivity disorder in obese melanocortin-4-receptor [MC4R] deficient subjects: a newly described expression of MC4R deficiency. Am J Med Genet B Neuropsychiatr Genet 2008, 147B:1547-1553.
10. Pott W., Albayrak O., Hinney A., Hebebrand J., Pauli-Pott U. Successful treatment with atomoxetine of an adolescent boy with attention deficit/hyperactivity disorder, extreme obesity, and reduced melanocortin 4 receptor function. Obes Facts 2013, 6(1):109-115.
11. Cortese S., Vincenzi B. Obesity and ADHD: clinical and neurobiological implications. Curr Top Behav Neurosci 2012, 9:199-218.
12. Cortese S., Ramos Olazagasti M.A., Klein R.G., Castellanos F.X., Proal E., et al. Obesity in men with childhood ADHD: a 33-year controlled, prospective, follow-up study. Pediatrics 2013, 131(6):1731-1738.
13. Khalife N., Kantomaa M., Glover V., Tammelin T., Laitinen J., Ebeling H., et al. Childhood attention-deficit/hyperactivity disorder symptoms are risk factors for obesity and physical inactivity in adolescence. J Am Acad Child Adolesc Psychiatry 2014, 53(4):425-436.
14. Cortese S., Morcillo-Penalver C. Comorbidity between ADHD and obesity: exploring shared mechanisms and clinical implications. Postgrad Med 2010, 22(5):88-96.
15. Pandit R., de Jong J.W., Vanderschuren L.J., Adan R.A. Neurobiology of overeating and obesity: the role of melanocortin and beyond. Eur J Pharm 2011, 660:28-42.
16. Tao Y.X. The melanocortin-4-receptor: physiology, pharmacology and pathophysiology. Endocr Rev 2010, 31(4):506-543.
17. Boghossian S., Park M., York D.A. Melanocortin activity in the amygdala controls appetite for dietary fat. Am J Physiol Regul Integr Comp Physiol 2010, 298(2):R385-R393.
18. Florijn W.J., Holtmaat A.J., de Lang H., Spierenburg H., Gispen W.H., Versteeg D.H. Peptide-induced grooming behavior and caudate nucleus dopamine release. Brain Res 1993, 625(1):169-172.
19. Lindblom J., Opmane B., Mutulis F., Mutule I., Petrovska R., Klusa V., et al. The MC4 receptor mediates alpha-MSH induced release of nucleus accumbens dopamine. NeuroReport 2001, 12(10):2155-2158.
20. Volkow N.D., Wang G.J., Baler R.D. Reward, dopamine and the control of food intake: implications for obesity. Trends Cogn Sci 2011, 15(1):37-46.
21. Volkow N.D., Wang G.J., Kollins S.H., Wigal T.L., Newcorn J.H., Telang F., et al. Evaluating dopamine reward pathway in ADHD: clinical implications. JAMA 2010, 302(10):1084-1091.
22. Wang G.J., Volkow N.D., Logan J., Pappas N.R., Wong C.T., Zhu W., et al. Brain dopamine and obesity. Lancet 2001, 357:354-357.
23. Farooqi I.S., O'Rahilly S. Genetics of obesity in humans. Endocr Rev 2006, 27(7):710-718.
24. Hsu R., Taylor J.R., Newton S.S., Alvaro J.D., Haile C., Han G., et al. Blockade of melanocortin transmission inhibits cocaine reward. Eur J Neurosci 2005, 21(8):2233-2242.
25. Kelley A.E. Memory and addiction: shared neural circuitry and molecular mechanisms. Neuron 2004, 44:161-179.
26. Couceyro P.R., Evans C., McKinzie A., Mitchell D., Dube M., Hagshenas L., et al. Cocaine- and amphetamine-regulated transcript (CART) peptides modulate the locomotor and motivational properties of psychostimulants. J Pharmacol Exp Ther 2005, 315(3):1091-1100.
27. Ahn J.D., Dubern B., Lubrano-Berthelier C., Clement K., Karsenty G. Cart overexpression is the only identifiable cause of high bone mass in melanocortin 4 receptor deficiency. Endocrinology 2006, 147(7):3196-3202.
28. Schertz M., Adesman A.R., Alfieri N.E., Bienkowski R.S. Predictors of weight loss in children with attention deficit hyperactivity disorder treated with stimulant medication. Pediatrics 1996, 98:763-769.
29. Hainerová I., Larsen L.H., Holst B., Finková M., Hainer V., Lebl J., et al. Melanocortin 4 receptor mutations in obese Czech children: studies of prevalence, phenotype development, weight reduction response, and functional analysis. J Clin Endocrinol Metab 2007, 92(9):3689-3696.